Also, significantly elevated plasma syndecan-1 levels were seen in patients who developed early coagulopathy (33.7(21.6–109.5) ng/mL) as compared to those who did not (29.9(19.2–39.5) ng/mL; p = 0.03), and the control group (p = 0.04) (Figure 2 and Table 2). This evidence concerns the gene SDC1 and blood coagulation disease.